Personalised & Actionable Reporting

Example of report's main features; content as per the latest AMP and CAP guidelines



Patient, ordering physician and specimen information at a glance.

Comprehensive overview of important findings at a glance summarising:
- Identified variants
- Recommended targeted therapies
- Low-impact therapies
- Possible clinical trials

Relevant biomarkers sorted by strength of clinical significance.

Detail description for all detected variants:
- Variant interpretation
- Clinical impact
- Possible therapies
- Indications & prognosis
- Literatures references

Interpretation and potential significance of genomics signatures.

Ongoing clinical trials within the region:
- Name & link of clinical trial
- Phase of trial
- Targeted variant

OncoStrands© Step-by-Step Ordering Procedure

Specimen Requirements

FFPE tissue/cell block (preferred) or slides with at least 10-20% tumour purity.
Refer to Specimen Collection Instructions for more information.

1. Test selection based on patient's case and pathology findings.
2. Ordering physician completes test request form (TRF) and sends tumour block or slides to LifeStrands Genomics laboratory.
3. Sample accessioning and testing will be performed upon sample reception at testing laboratory.
4. Results will be made available within 7- 15 working days through ordering physician's preferred receiving means.
5. Tumour block is returned to issuing pathology laboratory immediately after release of final report (slides will not be returned).

LifeStrands

Our mission is to empower lives through genomics; revolutionise personalised healthcare towards a patient-centric approach by providing more accurate and clinically relevant testing with better accessibility.

Australia | Singapore | Malaysia

enquiry@lifestrandsgx.com

www.lifestrandsgx.com

OncoStrands®

ESSENTIAL | EXTENDED | COMPREHENSIVE

Unravel tumour profiling through broad acess in precision oncology

ONE Biospy, ONE Test, ONE Actionable Report

Unlock cancer genetic information and improve patient outcomes by receiving therapy options sooner. OncoStrands® covers one of the broadest panel selections of clinically relevant genes existing today, from the Essentials to the most Comprehensive, offering a unique combination of various genomic alterations (DNA, RNA fusions, CNVs, Indels, splice variants) and signatures (TMB, MSI, HRD), providing clear clinical guidance based on current FDA, EMA, NCCN and ESMO guidelines.

LifeStrands
Empowering lives with Genomics

Key Biomarkers per Tumour Type

(genes listed covered through various OncoStrands© NGS panels)

Melanocyte

BRAF CTNNB1 GNA11 GNAQ KIT MAP2K1 NF1 NRAS PDGFRA PIK3CA PTEN ROS1 TP53

Breast

AKT1 ATM AR BRCA1 BRCA2 CDH1 CHEK2 ERBB2 ESR1 FGFR1 FGFR2 MLH1 MSH2 MSH6 NBN PALB2 PIK3CA PTEN RAD51C STK11 TP53

Liver

ARID1A AXIN1 BRAF CCND1 CDKN2A CTNNB1 FGFR2 IDH1 JAK1 PIK3CA PTEN VEGFA TERT TP53

Pancreas

ARID1A BRAF BRCA1 BRCA2 CDK12 CDKN2A EGFR EP300 FBXW7 HRAS KRAS MLH1 MSH2 NOTCH1 NOTCH2 PALB2 PIK3CA PTEN STK11 TP53

Cervix, Uterus & Ovary*

AKT1 ARID1A ATR BARD1 BRAF BRCA1 BRCA2 CDK12 CDKN2A ERBB2 ESR1 FGFR1 FGFR2 FGFR3 FOXO1 FOXL2 JAZF1 KRAS NCOA2 NCOA3 NRG1 NUTM2A NUTM2B PAX3 PAX7 PDGFRA PHF1 POLE PTEN RAD51C SMARCA4 SUZ12 TP53 YWHAE



Brain & CNS

ALK APC ATRX BRAF CDKN2A CDKN2B CTNNB1 EGFR H3F3A HIST1H3B IDH1 IDH2 MET MYC MYCN NF1 PDGFRA PTCH1 REL TERT TP53

Head & Neck

AR ARID1A BRAF CDK12 CDKN2A EGFR EP300 ERBB2 FBXW7 FGFR1 FGFR2 FGFR3 HRAS KRAS NOTCH1 NOTCH2 PIK3CA TP53

Lung

AKT1 ALK BRAF DDR2 EGFR ERBB2 FGFR1 FGFR3 HRAS KRAS MAP2K1 MET NRAS NUTM1 PIK3CA PTEN RET ROS1 RICTOR TP53

Stomach

APC ARID1A ATR BRAF EGFR FGFR1 FGFR2 HRAS KIT KRAS MET MLH1 MSH2 MSH6 NF1 NRAS PDGFRA PMS2 STK11 SMAD4 TP53

Colorectal

AKT1 APC ATM BRAF CDH1 CHEK2 EGFR ERRB2 HRAS KRAS MET MLH1 MSH2 MSH6 MUTYH NRAS PIK3CA PMS2 PTEN SMAD4 STK11 TP53

Bladder

ATM ERBB3 FGFR2 FGFR3 MTOR RB1 TSC1

Prostate

AR ATM ARID1A BARD1 BRAF BRCA1 BRCA2 BRIP1 CDK12 CDKN2A CHEK1 CHEK2 FANCL FGFR2 FGFR3 PALB2 PTEN RAD51B RAD51C RAD51D RAD54L TMPRSS2

Homologous Recomination Deficiency*

(HRD; Genomic Scaring)

Loss of heterozygosity (LOH)
Telomeric-Allelic Imbalance (TAI)
Large-scale State Transitions (LST)

All Solid Tumours

(pan-cancer biomarkers)

Tumour Mutational Burder (TMB)
Microsatellite Instability (MSI)
NTRK Fusions (*NTRK1, NTRK2, NTRK3*)

Listed biomarkers available from the following panels[1]:

Essential (50 genes)
Extended (109 genes)
Comprehensive (523 genes)

Supplementary Tests

(to aid further treatment decisions)

Immunohistochemistry (IHC)

PD-L1 MMR ALK ROS1

Promoter Methylation

MLH1 MGMT

*Powered by Myriad Genetics' proprietary algorithm and is available for Ovarian cancer ONLY.

[1]Colour-coded biomarkers indicate genes coverage from smallest available panel, which are also available in larger panels, e.g. *NF1* is only covered in the Extended & Comprehensive panels, but not Essential panel.
Genes listed are non-exhaustive, full genes list available upon request.